INSM · XBRL financial data

INSMED financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (INSM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	84*	76	90	93	104*	93	107	142	264*	306	425	524
Cost of goods and services sold	18*	17	21	21	26*	21	28	29	44*	47	67	78
Research and development	137*	121	147	151	180*	153	177	186	255*	209	210	270
Selling, general and administrative	year only	93	107	119	143*	148	155	186	212*	247	247	253
General and administrative	90*	93	107	119	—	—	—	—	—	—	—	—
Operating income (loss)	(178)*	(146)	(289)	(213)	(230)*	(248)	(313)	(366)	(320)*	(153)	(2)	(89)
Interest expense	21*	21	21	21	22*	22	21	20	21*	20	20	20
Other income (expense)	2*	(1)	(0)	2	(0)*	0	0	(1)	(2)*	(1)	(1)	1
Income tax expense (benefit)	1*	1	1	1	1*	1	1	1	2*	1	2	3
Net income (loss)	(186)*	(157)	(301)	(221)	(236)*	(257)	(322)	(370)	(328)*	(164)	(13)	(100)
Earnings per share, basic USD per share	(1.28)*	(1.06)	(1.94)	(1.27)	(1.32)*	(1.42)	(1.70)	(1.75)	(1.54)*	(0.76)	(0.06)	(0.46)
Earnings per share, diluted USD per share	(1.28)*	(1.06)	(1.94)	(1.27)	(1.32)*	(1.42)	(1.70)	(1.75)	(1.54)*	(0.76)	(0.06)	(0.46)
Weighted average shares, basic millions of shares	145*	148	155	174	179*	181	189	212	214*	215	217	219
Weighted average shares, diluted millions of shares	145*	148	155	174	179*	181	189	212	214*	215	217	219

Balance sheet

CSV

Fiscal quarters (INSM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	482	596	1,247	461	555	403	1,284	335	510	582	545	397
Marketable securities	298	0	0	1,006	879	796	572	1,345	920	641	616	750
Accounts receivable	41	37	40	42	52	48	55	65	141	179	215	259
Inventory	83	83	90	98	99	101	108	121	132	133	142	164
Prepaid and other current assets	24	43	41	41	37	55	62	66	91	78	116	137
Total current assets	929	759	1,418	1,650	1,622	1,403	2,082	1,932	1,794	1,613	1,634	1,707
Property and equipment, net	65	69	73	75	80	88	90	90	103	103	107	108
Right-of-use asset	18	17	16	16	17	11	10	11	21	14	13	18
Goodwill	136	136	136	136	136	136	136	136	136	136	136	136
Total assets	1,330	1,159	1,810	2,053	2,025	1,803	2,480	2,361	2,265	2,076	2,103	2,226
Accounts payable	65	44	51	65	73	58	74	80	80	73	75	84
Current portion of long-term debt	0	224	224	—	—	—	—	—	0	—	—	10
Total current liabilities	226	421	524	259	298	239	312	417	469	361	439	597
Long-term debt	1,155	939	947	955	1,103	1,105	539	540	541	542	544	545
Lease liability, non-current	11	14	12	10	9	8	8	8	12	10	8	10
Total liabilities	1,662	1,624	1,771	1,570	1,740	1,704	1,230	1,415	1,526	1,371	1,345	1,500
Accumulated deficit	(3,446)	(3,603)	(3,904)	(4,124)	(4,360)	(4,617)	(4,938)	(5,308)	(5,637)	(5,800)	(5,813)	(5,914)
Total stockholders' equity	(332)	(465)	39	483	285	99	1,250	946	739	705	757	726
Total liabilities and equity	1,330	1,159	1,810	2,053	2,025	1,803	2,480	2,361	2,265	2,076	2,103	2,226
Common shares outstanding (cover page) millions of shares	148	149	172	179	181	182	211	213	216	217	218	219

Cash flows

CSV

Fiscal quarters (INSM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(186)*	(157)	(301)	(221)	(236)*	(257)	(322)	(370)	(328)*	(164)	(13)	(100)
Stock-based compensation	20*	21	23*	26*	27*	39	43*	31*	39*	46	41*	41*
Depreciation and amortization	year only	—	—	—	—	—	—	—	—	—	—	—
Net cash from operating activities	(131)*	(184)	(123)*	(181)*	(196)*	(262)	(206)*	(220)*	(248)*	(223)	(89)*	(36)*
Purchases of property and equipment	2*	5	7*	4*	7*	10	3*	2*	17*	3	6*	6*
Net cash from investing activities	2*	295	(7)*	(1,003)*	132*	80	228*	(762)*	389*	266	25*	(136)*
Proceeds from issuing common stock	114*	—	—	371*	(0)*	—	—	(0)*	0*	—	—	0*
Net cash from financing activities	123*	3	781*	397*	159*	29	858*	33*	34*	30	27*	24*
Net change in cash	(5)*	113	651*	(785)*	94*	(152)	881*	(950)*	176*	72	(37)*	(148)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
INSMED	397	524	(36)*	219.4M	—	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
United Therapeutics	1,803	783	314*	42.9M	—	Q2 FY26 10-QJun 30, 2026
Alnylam Pharmaceuticals	1,754	1,458	341*	133.9M	—	Q3 FY26 10-QSep 30, 2026
Idexx Laboratories	198	1,214	450*	78.8M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.